Stoke Therapeutics Quarterly Cash Flow Statement
NASDAQ: STOKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Stoke Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Stoke Therapeutics generated -$56.6 million of operating cash flow and spent $2.0 million on capital expenditures. That left free cash flow of -$58.6 million, a free-cash-flow margin of -628.0% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Stoke Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -61.62M | -50.00M | -57.93M | -38.35M | -23.48M | 112.88M | -10.48M | -26.43M | -25.70M | -26.37M | -26.96M | -24.54M |
| Net Income growth (YoY) | — | -144.30% | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 458.00K | 439.00K | 405.00K | 442.00K | 446.00K | 477.00K | 526.00K | 540.00K | 548.00K | 563.00K | 624.00K | 637.00K |
| Stock-Based Compensation | 10.80M | 8.75M | 9.85M | 8.04M | 7.60M | 6.75M | 7.14M | 7.49M | 7.43M | 5.41M | 6.06M | 6.55M |
| Change in Working Capital | -9.14M | -4.29M | 8.07M | -6.00M | -13.89M | 6.87M | -22.36M | -2.15M | -3.61M | -2.77M | 274.00K | -351.00K |
| Operating Cash Flow | -56.59M | -60.58M | -30.45M | -30.37M | -25.42M | 131.83M | -23.19M | -21.61M | -17.48M | -24.57M | -20.65M | -17.26M |
| Capital Expenditures | -1.98M | -353.00K | -232.00K | -132.00K | -154.00K | -152.00K | -42.00K | -103.00K | -46.00K | -12.00K | -229.00K | -383.00K |
| Investing Cash Flow | 9.02M | 50.69M | -61.06M | 9.09M | -148.48M | 13.63M | 819.00K | -30.00M | -88.28M | 9.99M | 14.77M | 14.62M |
| Financing Cash Flow | 1.91M | 84.33M | 92.34M | 3.12M | 554.00K | 1.37M | 568.00K | 8.16M | 120.65M | 1.72M | 7.34M | 562.00K |
| Net Change in Cash | -45.66M | 74.44M | 826.00K | -18.15M | -173.34M | 146.83M | -21.81M | -43.46M | 14.89M | -12.86M | 1.47M | -2.08M |
| Free Cash Flow | -58.56M | -60.94M | -30.69M | -30.50M | -25.58M | 131.68M | -23.23M | -21.72M | -17.52M | -24.58M | -20.88M | -17.64M |
This table shows 12 quarterly periods of Stoke Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow STOK's reporting calendar. What is a cash flow statement?